Literature DB >> 9414287

Transcriptional regulatory elements within the first intron of Bruton's tyrosine kinase.

J Rohrer1, M E Conley.   

Abstract

Defects in the gene for Bruton's tyrosine kinase (Btk) result in the disorder X-linked agammaglobulinemia (XLA). Whereas XLA is characterized by a profound defect in B-cell development, Btk is expressed in both the B lymphocyte and myeloid cell lineages. We evaluated a patient with XLA who had reduced amounts of Btk transcript but no abnormalities in his coding sequence. A single base-pair substitution in the first intron of Btk was identified in this patient, suggesting that this region may contain regulatory elements. Using reporter constructs we identified two transcriptional control elements in the first 500 bp of intron 1. A strong positive regulator, active in both pre-B cells and B cells, was identified within the first 43 bp of the intron. Gel-shift assays identified two Sp1 binding sites within this element. The patient's mutation results in an altered binding specificity of the proximal Sp1 binding site. A negative regulator, active in pre-B cells only, was located between base pairs 281 and 491 of the intron. These findings indicate that regulation of Btk transcription is complex and may involve several transcriptional regulatory factors at the different stages of B-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9414287

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

3.  Mutations in btk in patients with presumed X-linked agammaglobulinemia.

Authors:  M E Conley; D Mathias; J Treadaway; Y Minegishi; J Rohrer
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

4.  Genome-wide functional analysis of human 5' untranslated region introns.

Authors:  Can Cenik; Adnan Derti; Joseph C Mellor; Gabriel F Berriz; Frederick P Roth
Journal:  Genome Biol       Date:  2010-03-11       Impact factor: 13.583

5.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

6.  Association Between KCNQ1 Genetic Variants and Type 2 Diabetes in the Uyghur Population.

Authors:  Qi Ma; Li Wang; Hua Yao; Ting-ting Wang; Yan Ma; Yin-xia Su; Zhi-qiang Wang; Jun Zhu; Shu-xia Wang; Zhao-Xia Zhang; Qin-qin Hou; Ren Cai; Xue-li Gong; Xiao-yan Jiang
Journal:  Genet Test Mol Biomarkers       Date:  2015-11-05

7.  Properties of non-coding DNA and identification of putative cis-regulatory elements in Theileria parva.

Authors:  Xiang Guo; Joana C Silva
Journal:  BMC Genomics       Date:  2008-12-03       Impact factor: 3.969

8.  The word landscape of the non-coding segments of the Arabidopsis thaliana genome.

Authors:  Jens Lichtenberg; Alper Yilmaz; Joshua D Welch; Kyle Kurz; Xiaoyu Liang; Frank Drews; Klaus Ecker; Stephen S Lee; Matt Geisler; Erich Grotewold; Lonnie R Welch
Journal:  BMC Genomics       Date:  2009-10-08       Impact factor: 3.969

9.  Regulation of prion protein expression: a potential site for therapeutic intervention in the transmissible spongiform encephalopathies.

Authors:  C L Haigh; D R Brown
Journal:  Int J Biomed Sci       Date:  2006-12

10.  Btk expression is controlled by Oct and BOB.1/OBF.1.

Authors:  Cornelia Brunner; Thomas Wirth
Journal:  Nucleic Acids Res       Date:  2006-03-31       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.